Eli Lilly (LLY) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Eli Lilly and Company (LLY) insider buying and selling: no purchases, 42 sales
156 Form 4 Table I transactions filed with the SEC by Eli Lilly and Company insiders between 2025-08-28 and 2026-10-20 (15-month history): 0 open-market purchases and 42 sales, plus 114 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $322.4M by Lilly Endowment Inc on 2026-01-07.
Eli Lilly insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Eli Lilly insiders filed 29 sales worth $2.48B on the open market, and no purchases. 1 of those trade arrives with no usable amount on the filing and adds $0 here.
The biggest seller was Lilly Endowment Inc (Officer): $2.46B in 24 sales, out of 5 different sellers.
The largest trade of the period was a sale of $322.4M on Jan 7, 2026, by Lilly Endowment Inc (10% Owner). Form 4 on sec.gov (0000316011-26-000003).
Of the 29 sales, 5 (17%, $19.8M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 24 do not.
The last three months show 3 sales, against 2 in the three before. The latest sale from Aug 17, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Eli Lilly has more sales than 51 of the other 58, ranks 1 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with LLY's sales, largest first. The full history is in the tool above, already searched.
See all 156 LLY trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-01-07 | 2026-01-08 | Lilly Endowment Inc | 10% Owner | $322.4M | S — Open-market sale30 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,085.00 to $1,085.60, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), (27), (28), (29), and (30) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,086.28 to $1,087.06, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,087.45 to $1,088.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,088.50 to $1,089.32, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,089.79 to $1,090.78, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,090.88 to $1,091.51, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,091.97 to $1,092.80, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,093.41 to $1,093.61, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,094.56 to $1,094.85, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,095.71 to $1,095.89, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,096.87 to $1,097.83, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,097.87 to $1,098.82, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,098.87 to $1,099.86, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,099.88 to $1,100.85, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,100.88 to $1,101.87, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,101.88 to $1,102.87, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,102.88 to $1,103.86, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,103.88 to $1,104.87, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,104.88 to $1,105.87, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,105.88 to $1,106.87, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,106.93 to $1,107.92, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,107.93 to $1,108.92, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,108.94 to $1,109.91, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,110.00 to $1,110.94, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,111.01 to $1,112.00, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,112.03 to $1,113.00, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,113.05 to $1,114.01, inclusive. F28 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,114.05 to $1,115.00, inclusive. F29 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,115.11 to $1,116.07, inclusive. F30 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,116.15 to $1,117.11, inclusive. | SEC |
| 2025-11-12 | 2025-11-13 | Lilly Endowment Inc | 10% Owner | $308.4M | S — Open-market sale20 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,001.213 to $1,002.20, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), and (20) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,002.52 to $1,003.51, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,003.52 to $1,004.515, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,004.53 to $1,005.527, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,005.535 to $1,006.53, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,006.54 to $1,007.53, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,007.54 to $1,008.52, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,008.54 to $1,009.535, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,009.54 to $1,010.53, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,010.54 to $1,011.53, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,011.55 to $1,012.545, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,012.55 to $1,013.532, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,013.59 to $1,014.56, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,014.59 to $1,015.58, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,015.59 to $1,016.439, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,016.60 to $1,017.54, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,017.63 to $1,018.62, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,018.65 to $1,019.421, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,019.651 to $1,020.375 inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,020.664 to $1,021.661, inclusive. | SEC |
| 2025-11-11 | 2025-11-12 | Lilly Endowment Inc | 10% Owner | $279.3M | S — Open-market sale27 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $972.00 to $972.995, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), and (27) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $973.00 to $973.98, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $974.00 to $974.99, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $975.00 to $975.98, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $976.07 to $977.01, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $977.205 to $978.12, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $978.23 to $979.19, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $979.235 to $980.23, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $980.24 to $981.115, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $981.50 to $982.48, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $982.525 to $983.50, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $983.56 to $984.51, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $984.59 to $985.585, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $985.60 to $986.58, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $986.605 to $987.60, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $987.61 to $988.49, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $988.63 to $989.62, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $989.63 to $990.62, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $990.63 to $991.605, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $991.65 to $992.60, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $992.685 to $993.66, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $993.70 to $994.68, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $994.75 to $995.67, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $995.76 to $996.75, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $996.78 to $997.75, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $997.81 to $998.80, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $998.81 to $999.49, inclusive. | SEC |
| 2025-11-03 | 2025-11-04 | Lilly Endowment Inc | 10% Owner | $266.6M | S — Open-market sale24 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $877.00 to $877.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), and (24) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $878.00 to $878.99, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $879.00 to $879.80, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $880.00 to $880.99, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $881.00 to $881.98, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $882.00 to $882.99, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $883.14 to $884.12, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $884.145 to $885.14, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $885.145 to $886.14, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $886.145 to $886.48, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $887.50 to $888.41, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $888.58 to $889.52, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $889.615 to $890.61, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $890.615 to $891.61, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $891.62 to $892.515, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $892.675 to $893.62, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $893.69 to $894.68, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $894.69 to $895.68, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $895.69 to $896.685, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $896.69 to $897.665, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $897.69 to $898.67, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $898.70 to $899.69, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $899.70 to $900.62, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $900.77 to $901.295, inclusive. | SEC |
| 2025-10-31 | 2025-11-03 | Lilly Endowment Inc | 10% Owner | $260.2M | S — Open-market sale8 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.00 to $862.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $863.00 to $863.9999, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $864.00 to $864.9985, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $865.00 to $865.99, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $866.00 to $866.997, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $867.00 to $867.9983, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $868.00 to $868.9994, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $869.0023 to $869.9057, inclusive. | SEC |
| 2025-10-01 | 2025-10-02 | Lilly Endowment Inc | 10% Owner | $177.3M | S — Open-market sale25 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $807.85 to $808.70, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), and (25) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $808.86 to $809.825, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $809.86 to $810.78, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.00 to $811.905, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.00 to $812.99, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $813.00 to $813.88, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.00 to $814.975, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $815.00 to $815.97, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $816.08 to $816.82, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $817.125 to $818.00, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $818.18 to $819.07, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $819.27 to $820.20, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $820.40 to $821.31, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $821.55 to $822.495, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $822.78 to $823.71, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $823.91 to $824.88, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $824.91 to $825.905, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $825.91 to $826.89, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $826.935 to $827.91, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $827.95 to $828.94, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $828.96 to $829.93, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $829.98 to $830.9675, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $831.00 to $831.84, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $832.00 to $832.98, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $833.11 to $833.155, inclusive. | SEC |
| 2025-11-19 | 2025-11-20 | Lilly Endowment Inc | 10% Owner | $176.1M | S — Open-market sale6 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,050.00 to $1,050.999, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), and (6) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,051.00 to $1,051.999, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,052.00 to $1,052.999, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,053.00 to $1,053.993, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,054.00 to $1,054.996, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,055.00 to $1,055.54, inclusive. | SEC |
| 2025-11-05 | 2025-11-06 | Lilly Endowment Inc | 10% Owner | $167.1M | S — Open-market sale29 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $910.90 to $911.415, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), (27), (28), and (29) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $913.36 to $914.31, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $914.59 to $915.46, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $916.76 to $917.38, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $920.99 to $921.98, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $921.99 to $922.985, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $922.99 to $923.97, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $923.99 to $924.835, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $925.77 to $926.71, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $926.77 to $927.76, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $927.78 to $928.765, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $928.78 to $929.77, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $929.78 to $930.77, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $930.79 to $931.77, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $931.80 to $932.7975, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $932.80 to $933.78, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $933.84 to $934.76, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $934.84 to $935.78, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $936.00 to $936.99, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $937.00 to $937.99, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $938.00 to $938.99, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $939.00 to $939.99, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $940.00 to $940.99, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $941.03 to $941.695, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $942.05 to $942.99, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $943.09 to $944.06, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $944.10 to $945.09, inclusive. F28 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $945.13 to $946.125, inclusive. F29 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $946.14 to $947.06, inclusive. | SEC |
| 2025-10-03 | 2025-10-06 | Lilly Endowment Inc | 10% Owner | $161.2M | S — Open-market sale24 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $821.00 to $821.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), and (24) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $822.0042 to $822.8284, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $823.0569 to $824.04, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $824.06 to $825.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $825.0661 to $826.00, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $826.0686 to $827.00, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $827.1055 to $827.915, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $829.57 to $830.1886, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $830.80 to $831.55, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $833.2044 to $834.196, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $834.25 to $835.245, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $835.27 to $836.24, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $836.29 to $837.28, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $837.29 to $838.285, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $838.30 to $839.29, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $839.31 to $840.30, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $840.34 to $841.32, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $841.34 to $842.32, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $842.37 to $843.3544, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $843.38 to $844.3795, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $844.38 to $845.34, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $845.40 to $846.39, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $846.45 to $847.39, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $847.49 to $847.63, inclusive. | SEC |
| 2025-11-25 | 2025-11-26 | Lilly Endowment Inc | 10% Owner | $161.1M | S — Open-market sale30 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,073.78 to $1,074.77, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), (27), (28), (29), and (30) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,075.50 to $1,076.47, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,077.64 to $1,078.38, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,078.84 to $1,079.52, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,080.10 to $1,081.00, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,081.36 to $1,082.25, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,082.82 to $1,083.00, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,084.50 to $1,085.45, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,085.50 to $1,086.45, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,086.50 to $1,087.49, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,087.50 to $1,088.48, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,088.50 to $1,089.47, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,089.51 to $1,090.46, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,090.57 to $1,091.55, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,091.58 to $1,092.57, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,092.58 to $1,093.57, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,093.58 to $1,094.53, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,094.65 to $1,095.32, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,095.86 to $1,096.70, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,096.87 to $1,097.86, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,097.87 to $1,098.84, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,098.87 to $1,099.85, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,099.87 to $1,100.83, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,100.87 to $1,101.86, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,101.87 to $1,102.86, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,102.97 to $1,103.96, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,103.97 to $1,104.96, inclusive. F28 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,104.97 to $1,105.96, inclusive. F29 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,105.99 to $1,106.98, inclusive. F30 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,107.00 to $1,107.95, inclusive. | SEC |
| 2025-11-24 | 2025-11-25 | Lilly Endowment Inc | 10% Owner | $152.1M | S — Open-market sale6 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,068.00 to $1,068.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), and (6) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,069.00 to $1,069.98, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,070.00 to $1,070.99, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,071.05 to $1,072.00, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,072.08 to $1,073.00, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,073.44 to $1,074.02, inclusive. | SEC |
| 2025-10-06 | 2025-10-07 | Lilly Endowment Inc | 10% Owner | $137.0M | S — Open-market sale8 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $848.00 to $848.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $849.005 to $850.00, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $850.055 to $851.01, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $851.055 to $852.035, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $852.14 to $853.13, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $853.17 to $854.13, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $854.22 to $855.00, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $855.50 to $856.375, inclusive. | SEC |
| 2025-11-21 | 2025-11-24 | Lilly Endowment Inc | 10% Owner | $111.5M | S — Open-market sale16 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,050.00 to $1,050.997, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), and (16) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,051.00 to $1,051.994, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,052.00 to $1,052.96, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,053.00 to $1,053.99, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,054.00 to $1,054.99, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,055.00 to $1,055.969, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,056.00 to $1,056.99, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,057.00 to $1,057.97, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,058.022 to $1,059.005, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,059.034 to $1,060.032, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,060.037 to $1,061.036, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,061.039 to $1,062.022, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,062.043 to $1,063.04, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,063.051 to $1,064.042, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,064.07 to $1,065.03, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,065.118 to $1,066.00, inclusive. | SEC |
| 2025-10-01 | 2025-10-02 | Lilly Endowment Inc | 10% Owner | $107.4M | S — Open-market sale27 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $773.03 to $773.59, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), and (27) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $774.93 to $775.08, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $779.683 to $780.6792, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $781.2358 to $782.0426, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $782.4486 to $783.4364, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $783.4551 to $784.4541, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $784.4883 to $785.4833, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $785.4949 to $786.4831, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $786.4962 to $787.4953, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $787.4967 to $788.4462, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $788.5097 to $789.4233, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $790.675 to $791.6708, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $791.6835 to $792.66, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $792.69 to $793.687, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $793.7117 to $794.705, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $794.7385 to $795.435, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $795.99 to $796.92, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $797.08 to $798.075, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $798.26 to $799.11, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $799.295 to $800.285, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $800.34 to $801.28, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $801.34 to $802.335, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $802.36 to $803.10, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $803.49 to $804.48, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $804.535 to $805.53, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $805.72 to $806.665, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $806.785 to $807.75, inclusive. | SEC |
| 2025-10-02 | 2025-10-03 | Lilly Endowment Inc | 10% Owner | $92.5M | S — Open-market sale8 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $821.00 to $821.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $822.00 to $822.84, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $823.00 to $823.91, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $824.0269 to $824.15, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $825.75 to $826.65, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $828.29 to $828.39, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $832.4959 to $833.4259, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $833.6277 to $834.23, inclusive. | SEC |
| 2025-09-30 | 2025-10-01 | Lilly Endowment Inc | 10% Owner | $86.8M | S — Open-market sale4 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $763.00 to $763.9997, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), and (4) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $764.00 to $764.9996, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $765.0001 to $765.9974, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $766.0029 to $766.2333, inclusive. | SEC |
| 2025-10-08 | 2025-10-09 | Lilly Endowment Inc | 10% Owner | $86.2M | S — Open-market sale7 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $848.00 to $848.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), and (7) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $849.00 to $849.99, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $850.00 to $850.99, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $851.00 to $851.98, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $852.05 to $853.01, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $853.25 to $854.21, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $854.42 to $855.25, inclusive. | SEC |
| 2025-09-18 | 2025-09-19 | Lilly Endowment Inc | 10% Owner | $81.5M | S — Open-market sale5 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $763.00 to $763.9993, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), and (5) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $764.00 to $764.9996, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $765.00 to $765.9883, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $766.00 to $766.9989, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $767.00 to $767.5958, inclusive. | SEC |
| 2025-11-18 | 2025-11-19 | Lilly Endowment Inc | 10% Owner | $62.3M | S — Open-market sale10 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,030.00 to $1,030.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), and (10) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,031.00 to $1,031.91, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,032.02 to $1,033.01, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,033.02 to $1,034.01, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,034.02 to $1,035.01, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,035.02 to $1,036.01, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,036.02 to $1,037.01, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,037.02 to $1,038.01, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,038.03 to $1,038.94, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,039.21 to $1,040.01, inclusive. | SEC |
| 2025-11-13 | 2025-11-14 | Lilly Endowment Inc | 10% Owner | $48.0M | S — Open-market sale2 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,030.00 to $1,030.96, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) and (2) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,031.58 to $1,032.14, inclusive. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Aug 28, 2025 and Oct 20, 2026 there is not one open-market purchase of Eli Lilly and Company: 42 sales worth $3.46B and zero dollars bought. Of those 42 open-market trades, 1 arrives with no usable amount —the filing reports no price, or reports one out of scale and the derived amount is voided—: it counts in the trade count and adds zero dollars here.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Eli Lilly and Company's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 78 | $99.7M |
| S | Open-market sale | 42 | $3.46B |
| F | Tax withholding (shares surrendered for taxes) | 14 | $34.8M |
| M | Option exercise | 14 | $0 |
| G | Gift | 8 | $0 |
| Total | Everything filed in the period | 156 | $3.60B |
23 of the 156 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 25 distinct people or entities have filed Eli Lilly and Company transactions: none bought on the open market and 5 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Lilly Endowment Inc | Officer | 36 | — | $3.44B (36) | 2026-05-07 |
| Jonsson Patrik | EVP & President, LLY Int'l | 4 | — | $7.6M (1) | 2026-08-18 |
| Hakim Anat | EVP, GC & Secretary | 4 | — | $6.0M (1) | 2026-08-10 |
| Zakrowski Donald A | SVP, Finance, & CAO | 6 | — | $4.1M (3) | 2026-08-11 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | 4 | — | $2.9M (1) | 2026-06-11 |
| Alvarez Ralph | Director | 14 | — | — | 2026-10-20 |
| Fyrwald J Erik | Director | 14 | — | — | 2026-10-20 |
| Luciano Juan R | Director | 14 | — | — | 2026-10-20 |
Shown here are the 8 who moved the most money, out of 25. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Nov 2025: 0 purchases and 18 sales, worth $1.86B. 6 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $735k |
| Sep 2025 | 0 | $0 | 3 | $186.4M |
| Oct 2025 | 0 | $0 | 10 | $1.06B |
| Nov 2025 | 0 | $0 | 18 | $1.86B |
| Dec 2025 | 0 | $0 | 3 | $7.0M |
| Jan 2026 | 0 | $0 | 2 | $323.9M |
| Feb 2026 | 0 | $0 | 0 | $0 |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 1 | $15.8M |
| Jun 2026 | 0 | $0 | 1 | $2.9M |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 3 | $16.0M |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Eli Lilly and Company (LLY) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 20 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Eli Lilly has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Oct 20, 2026, and a Form 4 arrives up to two business days after the trade.
20 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.